Literature DB >> 11442350

Distinct behavioral and neuropathological abnormalities in transgenic mouse models of HD and DRPLA.

G Schilling1, H A Jinnah, V Gonzales, M L Coonfield, Y Kim, J D Wood, D L Price, X J Li, N Jenkins, N Copeland, T Moran, C A Ross, D R Borchelt.   

Abstract

Huntington's disease (HD) and Dentatorubral and pallidoluysian atrophy (DRPLA) are autosomal dominant, neurodegenerative disorders caused by the expansion of polyglutamine tracts in their respective proteins, huntingtin and atrophin-1. We have previously generated mouse models of these disorders, using transgenes expressed via the prion protein promoter. Here, we report the first direct comparison of abnormalities in these models. The HD mice show abbreviated lifespans (4-6 months), hypoactivity, and mild impairment of motor skills. The DRPLA mice show severe tremors, are hyperactive, and are profoundly uncoordinated. Neuropathological analyses reveal that the distribution of diffuse nuclear immunolabeling and neuronal intranuclear inclusions (NII's), in the CNS of both models, was remarkably similar. Cytoplasmic aggregates of huntingtin were the major distinguishing neuropathological feature of the HD mice; mutant atrophin-1 accumulated/aggregated only in the nucleus. We suggest that the distinct behavioral and neuropathological phenotypes in these mice reflect differences in the way these mutant proteins perturb neuronal function. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11442350     DOI: 10.1006/nbdi.2001.0385

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  17 in total

1.  Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative.

Authors:  Andrew T N Tebbenkamp; Cameron Green; Guilian Xu; Eileen M Denovan-Wright; Aaron C Rising; Susan E Fromholt; Hilda H Brown; Debbie Swing; Ronald J Mandel; Lino Tessarollo; David R Borchelt
Journal:  Hum Mol Genet       Date:  2011-04-22       Impact factor: 6.150

2.  RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model.

Authors:  Scott Q Harper; Patrick D Staber; Xiaohua He; Steven L Eliason; Inês H Martins; Qinwen Mao; Linda Yang; Robert M Kotin; Henry L Paulson; Beverly L Davidson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-05       Impact factor: 11.205

Review 3.  Choosing an animal model for the study of Huntington's disease.

Authors:  Mahmoud A Pouladi; A Jennifer Morton; Michael R Hayden
Journal:  Nat Rev Neurosci       Date:  2013-10       Impact factor: 34.870

4.  Protein misfolding detected early in pathogenesis of transgenic mouse model of Huntington disease using amyloid seeding assay.

Authors:  Sharad Gupta; Shy'Ann Jie; David W Colby
Journal:  J Biol Chem       Date:  2011-12-20       Impact factor: 5.157

5.  G2019S-LRRK2 mutation enhances MPTP-linked Parkinsonism in mice.

Authors:  Nicolas Arbez; XiaoFei He; Yong Huang; Mark Ren; Yideng Liang; Frederick C Nucifora; Xiaofang Wang; Zhong Pei; Lino Tessarolo; Wanli W Smith; Christopher A Ross
Journal:  Hum Mol Genet       Date:  2020-03-13       Impact factor: 6.150

Review 6.  Gene-environment interplay in neurogenesis and neurodegeneration.

Authors:  Tomás Palomo; Trevor Archer; Richard J Beninger; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 7.  Mouse models of triplet repeat diseases.

Authors:  Gillian P Bates; Roman Gonitel
Journal:  Mol Biotechnol       Date:  2006-02       Impact factor: 2.695

8.  Overexpression of mutant ataxin-3 in mouse cerebellum induces ataxia and cerebellar neuropathology.

Authors:  Clévio Nóbrega; Isabel Nascimento-Ferreira; Isabel Onofre; David Albuquerque; Mariana Conceição; Nicole Déglon; Luís Pereira de Almeida
Journal:  Cerebellum       Date:  2013-08       Impact factor: 3.847

9.  A multidimensional approach to an in-depth proteomics analysis of transcriptional regulators in neuroblastoma cells.

Authors:  Qing Li; Mohit Raja Jain; Wei Chen; Hong Li
Journal:  J Neurosci Methods       Date:  2013-04-01       Impact factor: 2.390

10.  Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease.

Authors:  Jody Corey-Bloom; Haiqun Jia; Alaina M Aikin; Elizabeth A Thomas
Journal:  J Huntingtons Dis       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.